The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; Genentech; GlaxoSmithKline; Janssen; Lilly; Merck
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Abdel Saci
Employment - Bristol-Myers Squibb
 
Peter Szabo
Employment - Bristol-Myers Squibb
 
Li Wang
No Relationships to Disclose
 
Jun Zhu
Employment - Sema4
 
Alex Azrilevich
Employment - Bristol-Myers Squibb
 
Bruce S. Fischer
Employment - Bristol-Myers Squibb
 
Andrea Necchi
Consulting or Advisory Role - AstraZeneca; Bayer; Clovis Oncology; Merck Sharp & Dohme; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pierre Fabre; Roche
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Genentech; Inovio Pharmaceuticals; Janssen; Lilly; Merck; NCCN
Speakers' Bureau - Genentech
Research Funding - Bristol-Myers Squibb; Janssen; Michael and Sherry Sutton Fund for Urothelial Cancer; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Padmanee Sharma
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; Amgen (I); AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Constellation Pharmaceuticals; Constellation Pharmaceuticals (I); EMD Serono; EMD Serono (I); Evelo Therapeutics; Evelo Therapeutics (I); GlaxoSmithKline; GlaxoSmithKline (I); Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics; Neon Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)